BioCheetah Pte Ltd (Co. Reg. No. 201803287H) is a Singapore-based, A*STAR-IMCB spin-off diagnostics company. It is primarily set up to develop and commercialize non-invasive, protein-based immunodiagnostic applications. First diagnostic applications in development are based on the proprietary bladder cancer biomarkers and detection antibodies discovered and developed in IMCB by BioCheetah’s Scientific Founder (Prof. Jean-Paul Thiery) and the co-Founder/Chief Executive Officer (Dr. Kian-Chung Lee). Both Intellectual Property of bladder cancer biomarkers and detection antibodies are licensed from A*STAR. Products to be developed include professional use in-vitro diagnostic ELISA and Point-of-care test (POCT) kits. The kits will employ a novel multiplex urine-based biomarkers panel with high sensitivity and specificity for diagnosis and monitoring of bladder cancer. BioCheetah’s target markets are to encompass local and overseas public and private healthcare providers. BioCheetah is currently building an ISO 13485 facility at Block 79, JTC LaunchPad in Singapore and setting up its Quality Management System (QMS) for the purpose of design and development of its diagnostic products. In addition, clinical trials for clinical validation of the bladder cancer diagnostic products is currently underway with Singapore General Hospital and several hospitals in China.